Coconut ( DrugBank: Coconut )

3 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2
53	Sjogren syndrome	1
226	Interstitial cystitis with Hunners ulcer	1

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03740295 (ClinicalTrials.gov)	October 5, 2018	5/10/2018	Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis	Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: Coconut oil and epigallocatechin gallate;Other: Placebo	Fundación Universidad Católica de Valencia San Vicente Mártir	Valencian Institute of Neurorehabilitation Foundation	Completed	19 Years	65 Years	All	60	Phase 2	Spain
2	NCT01381354 (ClinicalTrials.gov)	October 2010	26/5/2011	Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)	Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)	Multiple Sclerosis	Other: Progressive exercise;Device: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV;Other: Modified paleolithic diet;Dietary Supplement: Omega 3 fatty acids;Dietary Supplement: Full Spectrum vitamin;Dietary Supplement: Essential - hydroxytyrosol;Dietary Supplement: Maltodextrin fiber supplement;Dietary Supplement: Mineral boost (magnesium);Dietary Supplement: Niacinamide;Dietary Supplement: Methyl B12;Dietary Supplement: Taurine;Dietary Supplement: creatine;Dietary Supplement: thiamine;Dietary Supplement: riboflavin;Dietary Supplement: N acetylcysteine;Dietary Supplement: alpha lipoic acid;Dietary Supplement: L acetyl carnitine;Dietary Supplement: methyl folate;Dietary Supplement: coenzyme Q;Behavioral: meditation;Behavioral: self massage;Behavioral: learning;Dietary Supplement: Coconut oil	University of Iowa	Direct MS Canada;DJO Incorporated;Pinnaclife Inc.;TZ Press, LLC	Completed	18 Years	65 Years	All	38	Phase 1	United States

53. Sjogren syndrome

Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04252209 (ClinicalTrials.gov)	August 2021	26/1/2020	the Effect of Mixture of Natural Products As Salivary Substitutes in Treatment Of Xerostomia	the Effect of Mixture of Natural Products As Salivary Substitute In Comparison To Carboxy Methyl Cellulose In Treatment Of Xerostomia In Patients With Sjogren's Syndrome: Cross Over Randomized Clinical Trial	Sjogren's Syndrome;Xerostomia	Other: natural herbs of coconut, aloe vera, and pepperint;Other: carboxy methyl cellulose	Cairo University	NULL	Not yet recruiting	18 Years	80 Years	All	44	Phase 3	NULL

226. Interstitial cystitis with Hunners ulcer

Clinical trials : 143 / Drugs : 171 - (DrugBank : 56) / Drug target genes : 64 - Drug target pathways : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04845217 (ClinicalTrials.gov)	September 15, 2021	29/3/2021	Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome	Efficacy of Peppermint Oil in a Randomized, Single-Blind, Placebo Controlled Trial in Women With Interstitial Cystitis/Bladder Pain Syndrome	Interstitial Cystitis	Drug: Peppermint oil;Drug: Coconut Oil	University of Louisville	Integrative Therapeutics, Inc.	Recruiting	18 Years	65 Years	Female	100	Phase 1/Phase 2	United States